Drug intelligence / Profile preview

S2G6T-4

Development stage: Unknown
Lead developer: Sol-Gel Technologies
Modality: Small Molecules
Administration: Topical

Overview

S2G6T-4 is an investigational small molecule drug developed by Sol-Gel Technologies for the treatment of symptomatic inflammatory interdigital tinea pedis, a fungal infection of the feet. It was evaluated in clinical trials alongside related products (S2G6T-1, S2G6T-2, and S2G6T-3) to compare efficacy and safety in patients with this condition. The drug appears to be part of a series of combination or single-agent topical antifungal therapies targeting skin infections. As of the latest available information, development has not advanced beyond early-phase clinical trials[3][7].

Other names: vehicle foam

Beyond the preview

Go deeper on S2G6T-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S2G6T-4.

Explore the full profile